Your browser is no longer supported. Please, upgrade your browser.
TAK [NYSE]
Takeda Pharmaceutical Company Limited
Index- P/E13.61 EPS (ttm)1.24 Insider Own0.01% Shs Outstand3.13B Perf Week-1.52%
Market Cap54.19B Forward P/E28.63 EPS next Y0.59 Insider Trans0.00% Shs Float3.13B Perf Month0.42%
Income3.91B PEG23.47 EPS next Q- Inst Own3.10% Short Float0.20% Perf Quarter-0.24%
Sales30.33B P/S1.79 EPS this Y745.90% Inst Trans-11.33% Short Ratio3.75 Perf Half Y-11.94%
Book/sh15.18 P/B1.11 EPS next Y- ROA3.40% Target Price21.65 Perf Year-8.85%
Cash/sh1.94 P/C8.72 EPS next 5Y0.58% ROE8.80% 52W Range15.30 - 19.97 Perf YTD-7.20%
Dividend0.85 P/FCF- EPS past 5Y- ROI5.30% 52W High-15.40% Beta1.07
Dividend %5.03% Quick Ratio1.00 Sales past 5Y- Gross Margin70.20% 52W Low10.37% ATR0.21
Employees47099 Current Ratio1.50 Sales Q/Q18.40% Oper. Margin17.70% RSI (14)49.08 Volatility1.03% 0.94%
OptionableYes Debt/Eq0.84 EPS Q/Q66.00% Profit Margin12.90% Rel Volume1.01 Prev Close17.15
ShortableYes LT Debt/Eq0.84 EarningsJul 30 BMO Payout- Avg Volume1.66M Price16.89
Recom2.30 SMA20-0.25% SMA500.49% SMA200-2.83% Volume1,699,634 Change-1.52%
Apr-19-21Downgrade JP Morgan Overweight → Neutral
Nov-01-19Initiated Cowen Market Perform $19.50
Aug-15-19Downgrade Daiwa Securities Outperform → Neutral
Sep-24-21 01:16PM  
Sep-22-21 09:30AM  
08:55AM  
Sep-21-21 11:00AM  
08:00AM  
Sep-16-21 06:08AM  
Sep-15-21 05:42PM  
04:40PM  
Sep-13-21 08:51PM  
Sep-07-21 04:05PM  
10:45AM  
07:51AM  
05:54AM  
Sep-06-21 10:53PM  
Sep-03-21 10:10AM  
Sep-02-21 10:09AM  
Sep-01-21 04:31PM  
09:47AM  
08:10AM  
05:25AM  
02:25AM  
Aug-31-21 01:25PM  
11:17AM  
Aug-30-21 08:52AM  
03:08AM  
Aug-29-21 08:46PM  
08:34PM  
Aug-28-21 10:11PM  
04:29AM  
Aug-26-21 11:46AM  
07:51AM  
Aug-25-21 07:54PM  
Aug-19-21 10:23AM  
Aug-18-21 11:00AM  
Aug-10-21 03:54PM  
09:47AM  
Aug-05-21 07:00AM  
Aug-02-21 10:26AM  
Aug-01-21 09:10PM  
08:55PM  
07:30PM  
Jul-30-21 05:50AM  
02:00AM  
Jul-29-21 08:30AM  
Jul-28-21 08:15AM  
Jul-22-21 12:10PM  
Jul-20-21 03:00PM  
07:16AM  
06:51AM  
05:40AM  
04:38AM  
Jul-19-21 06:30AM  
Jul-10-21 04:15AM  
Jul-09-21 07:15AM  
Jun-29-21 07:30AM  
Jun-28-21 05:05AM  
Jun-16-21 11:59AM  
Jun-09-21 12:21PM  
Jun-07-21 08:00AM  
Jun-04-21 09:38AM  
May-25-21 06:45PM  
May-24-21 08:05AM  
May-22-21 11:15AM  
May-21-21 04:30AM  
12:53AM  
May-20-21 04:39PM  
07:37AM  
May-19-21 05:01PM  
05:01PM  
May-11-21 05:46AM  
05:45AM  
02:35AM  
May-07-21 09:17AM  
May-03-21 06:33AM  
Apr-28-21 07:00AM  
Apr-27-21 05:30PM  
Apr-24-21 06:28AM  
Apr-14-21 06:30AM  
Apr-13-21 03:00PM  
Apr-05-21 04:12PM  
11:48AM  
Apr-01-21 10:18AM  
Mar-31-21 09:42AM  
02:00AM  
Mar-30-21 01:56PM  
Mar-26-21 12:59AM  
Mar-25-21 04:15PM  
Mar-18-21 12:09PM  
Mar-17-21 04:00AM  
Mar-15-21 04:16PM  
02:00PM  
09:06AM  
09:06AM  
07:49AM  
07:30AM  
Mar-12-21 02:00AM  
Mar-11-21 08:30AM  
Mar-10-21 08:00AM  
Mar-09-21 04:55PM  
04:17PM  
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.